GLP-1 Medications and Breast Cancer: What the Research Says So Far
A clear, balanced look at a fast-moving area of research, and what it means for people living with and beyond breast cancer.
By Laura Carfang, Ed.D. EDUCATION | NUTRITION & DIET
You've probably heard the names: Ozempic, Wegovy, Mounjaro, Zepbound. These medications are everywhere right now, in the news, on social media, and in conversations with friends.
In our breast cancer community, the questions come up often. Is it safe for me be on a GLP-1? Could it help lower my risk of the cancer coming back? Can I take it while I'm on treatment?
These are smart questions, and they deserve honest answers. The short version: the research is promising in places, early in others, and not yet settled. Here's what we know so far.
Takeaways
GLP-1 medications such as semaglutide and tirzepatide were developed for diabetes and are now also used for weight management.
A review of 52 randomized trials found no increase in breast cancer risk with GLP-1 medications.
A large 2026 study linked GLP-1 use to lower recurrence and death in breast cancer patients with obesity or diabetes, but it was observational and can’t prove cause and effect.
People with a history of breast cancer were excluded from the main GLP-1 trials, and breast cancer–specific trials are just beginning.
GLP-1s can affect how oral medications are absorbed and can add to treatment side effects, so decisions should involve your oncology team.
First, what are GLP-1 medications?
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally makes after you eat. It tells your body to release insulin, slows how quickly your stomach empties, and helps you feel full.
GLP-1 medications copy or boost this hormone, and their effects last much longer. They were first developed for type 2 diabetes. Some are now also approved for weight management and for lowering heart risk in certain people.
Common examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Tirzepatide acts on GLP-1 and a second hormone, GIP. We're naming them here only to help you recognize them, not to recommend any brand.
Why metabolic health matters in breast cancer
"Metabolic health" describes how well your body manages energy: blood sugar, insulin, body fat, cholesterol, and blood pressure. Researchers have long studied how it connects to breast cancer.
Here's what the evidence shows:
• Weight and outcomes are linked. Studies have associated obesity with a higher risk of breast cancer recurrence and death. The link appears strongest in postmenopausal women and in hormone receptor-positive breast cancer.
• Fat tissue makes estrogen. After menopause, body fat becomes a main source of estrogen, which can fuel hormone receptor-positive breast cancer.
• Insulin may play a role. Higher insulin levels have been tied to higher breast cancer risk and to worse outcomes in some studies, even in women without diabetes.
• Inflammation adds to the picture. Excess body fat is associated with ongoing, low-level inflammation that researchers believe may affect cancer growth.
Treatment itself can make this harder. Many people gain weight during chemotherapy, steroid use, or years of endocrine (hormone) therapy, and lose muscle along the way.
That's exactly why GLP-1 medications have caught researchers' attention. The question is whether they help people with breast cancer beyond managing weight and blood sugar.
One important note: weight is never a measure of your worth, and no one causes their own cancer. This is about understanding biology, not assigning blame.
What the research says right now
Do GLP-1 medications raise breast cancer risk?
Current evidence says no. A review of 52 randomized trials, covering more than 48,000 people on GLP-1 medications and nearly 41,000 who weren't, found no increase in breast cancer or in benign breast lumps. These trials were in people with diabetes or excess weight, not in breast cancer survivors specifically.
Could they lower the risk of recurrence?
This is where the headlines come from, and where it's important to slow down.
In May 2026, a large study in JAMA Network Open looked at health records from more than 841,000 patients with breast cancer. Among patients with obesity or type 2 diabetes, those who used GLP-1 medications had lower rates of death and recurrence over 10 years than similar patients who didn't.
That sounds dramatic, and it may turn out to be meaningful. But there are real limits:
• It's an observational study. It looked back at records. It didn't randomly assign people to a medication, so it can show a link but can't prove cause and effect.
• Other differences may explain it. People who get these medications may have better access to care, or other health differences that affect outcomes.
• Experts raised concerns. Some independent researchers questioned the study's methods and urged caution in drawing conclusions about breast cancer specifically.
• Heart health may be part of the story. Many women treated for breast cancer ultimately face heart disease, and GLP-1s are known to lower heart risk. That may explain some of the survival difference, but not necessarily the recurrence finding.
The study's own authors said clinical trials are needed before these medications can guide cancer treatment decisions.
What studies are underway?
Randomized trials designed specifically for breast cancer are just getting started. Examples include:
• A trial testing tirzepatide alongside standard hormone therapy in people with overweight or obesity and high-risk, hormone receptor-positive early breast cancer.
• A study of tirzepatide in women who are postmenopausal and have been diagnosed with HR+ breast cancer of hormone receptor-positive breast cancer with obesity, looking at weight, body composition, and overall health.
• A Mayo Clinic trial testing whether semaglutide plus lifestyle support improves heart and blood vessel health in survivors taking aromatase inhibitors.
These trials will take years. Until then, GLP-1 medications are not a breast cancer treatment, and they're not a substitute for proven therapies.
Risks and considerations
A history of breast cancer doesn't automatically rule out a GLP-1 medication. But it does mean the decision should be made together with your oncology team, not just the prescriber of the GLP-1. Here's what to weigh.
People with breast cancer weren't in the main trials. The large studies that led to FDA approval of semaglutide and tirzepatide for weight loss excluded people with a history of breast cancer. Early studies in survivors have found weight loss and side effects similar to people without cancer, but the data are still limited.
Effects on oral cancer medications. GLP-1s slow how quickly the stomach empties. That can change the timing of when pills are absorbed. Experts say this deserves a conversation if you take oral cancer drugs, such as anti-estrogen pills or capecitabine (Xeloda). Severe vomiting can also mean losing a dose entirely.
Overlapping side effects during treatment. Nausea, vomiting, constipation, and reduced appetite are common with GLP-1s, and with chemotherapy. Taking both can make it hard to tell what's causing what, and harder to eat enough. Many teams pause GLP-1s during intense treatment, but this is decided case by case.
Muscle and bone. A meaningful share of the weight lost on GLP-1s can come from muscle, not just fat. Cancer treatment can already reduce muscle and bone strength. Adequate protein, strength training, and nutrition support matter.
Thyroid history. People with a personal or family history of certain thyroid cancers (medullary thyroid cancer) or a related genetic syndrome are advised not to use these medications.
Cost and access. Coverage varies widely, and supply and pricing have shifted. Compounded or online versions aren't held to the same standards as FDA-approved products, so talk with your team before going that route.
Questions to bring to your care team
1. Given my diagnosis and treatment, is a GLP-1 medication something to consider for me?
2. Could it interact with any of my cancer medications, especially pills I take by mouth?
3. Should I pause it during chemotherapy, surgery, or other treatment?
4. How will we protect my muscle and bone health if I lose weight?
5. Who should manage this medication, and how will they coordinate with my oncologist?
6. Are there clinical trials studying GLP-1 medications in people like me?
7. What other ways can we support my metabolic health, like nutrition, physical activity, or sleep?
The bottom line
GLP-1 medications are one of the most talked-about developments in medicine, and their connection to breast cancer is worth watching closely. Early data are encouraging, and safety data so far are reassuring. But we don't yet have the randomized trials needed to know whether these medications change breast cancer outcomes.
For now, the best approach is an informed, individual conversation with your care team, one that weighs your health goals, your treatment, and the full picture of benefits and risks.
Read More:
On the Podcast: Breast Cancer Conversations
Episode 291. Breast Cancer Survivorship: Exercise, Nutrition, Sleep, and Support That Actually Matter | Dr. Amy Comander & Meg McSherry
